HPV Vaccine Benefits for Men: New Study Shows Cancer Risk Drop
A new study published in JAMA Oncology indicates that the HPV vaccine significantly reduces the risk of HPV-related cancers in males by approximately 46% compared to unvaccinated individuals. HPV is a common virus transmitted through skin-to-skin contact, linked to cancers in both men (e.g., anal, oropharyngeal, penile) and women (e.g., cervical). While initial focus was on cervical cancer, current medical consensus recommends vaccination for all adolescents. Experts confirm that while early vaccination is optimal, later 'catch-up' vaccination remains highly beneficial for protection against multiple HPV strains. Parents are advised to discuss vaccination timing and necessity with their healthcare provider.
Ad slot
A vaccine historically focused on women is now demonstrating significant cancer-preventive benefits for men and boys, according to a major new study. The research highlights that vaccination can substantially lower the risk of HPV-related cancers in males, prompting updated discussions among healthcare providers and parents.
Understanding HPV and Associated Cancers
Dr. Leana Wen, an emergency physician, explains that Human Papillomavirus (HPV) is an extremely common virus transmitted through intimate skin-to-skin contact, affecting both sexes.
Infection Rate: Nearly all sexually active individuals are expected to contract HPV within months to a few years of sexual activity.
Risk: About half of these infections involve high-risk HPV types, which increase the likelihood of developing cancer.
Persistence: While most infections clear naturally, some persist and can cause cellular changes that may become cancerous over time.
HPV is linked to various cancers in both men and women:
In Women: Cervical cancer (the most recognized), as well as cancers of the vagina and vulva.
In Men: Cancers of the penis, anus, and head and neck. Specific statistics cited include:
Over 90% of anal cancer cases are attributed to HPV.
Approximately 70% of oropharyngeal (throat) cancer is linked to HPV.
More than 60% of penile cancer is caused by HPV.
Key Findings on Male Vaccination
Ad slot
A large study analyzing a global database of over 615,000 males aged 9 to 26 found compelling evidence regarding male vaccination.
Overall Risk Reduction: Men who received the nonavalent HPV vaccine showed a significantly lower risk of developing HPV-related cancers—an estimated 46% reduction compared to unvaccinated men.
Age-Specific Benefits: The protective benefit varied by vaccination window:
Vaccinated between ages 9 and 14: Approximately 42% lower risk.
Vaccinated between ages 15 and 26: Approximately 50% lower risk.
Vaccination Recommendations and Timing
Historically, the vaccine's focus was on cervical cancer prevention. However, current guidelines emphasize broader protection for all genders.
CDC Recommendation: The US Centers for Disease Control and Prevention (CDC) recommends routine vaccination for preteens at ages 11 or 12, with the series starting as early as age 9.
AAP Guidance: The American Academy of Pediatrics (AAP) advises routine vaccination for all adolescents between 9 and 12 years old, aiming to vaccinate before any potential exposure.
Benefit of Later Vaccination: Experts stress that while early vaccination is ideal, there is still significant benefit for those who get vaccinated later in adolescence or young adulthood, as the vaccine protects against multiple HPV strains.
Catch-Up Care: Recommendations for those who missed the initial window include:
Through age 26: Catch-up vaccinations are advised.
Ages 27 to 45: The CDC recommends shared clinical decision-making with a healthcare provider, as the vaccine is licensed for these groups.
Conclusion for Parents
Experts advise parents that the primary goal of the HPV vaccine is cancer prevention. The vaccine's safety profile is well-established, and its effectiveness in preventing serious, long-term HPV-related diseases is considered very high.
